SGD-1910

SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala[1].

Product Specifications

CAS Number

[1342820-51-2]

UNSPSC

12352203

Target

Drug-Linker Conjugates for ADC

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mc-val-ala-pbd.html

Purity

96.17

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(OC)=C(OCCCOC(C=C(N=C[C@@]2([H])N(C=C(C3=CC=C(OC)C=C3)C2)C4=O)C4=C5)=C5OC)C=C1N=C6)N7[C@@]6([H])CC(C8=CC=C(NC([C@H](C)NC([C@H](C(C)C)NC(CCCCCN(C9=O)C(C=C9)=O)=O)=O)=O)C=C8)=C7

Molecular Formula

C60H64N8O12

Molecular Weight

1089.20

References & Citations

[1]Jeffrey SC, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013 Jul 17;24 (7) :1256-63.|[2]John A Hartley. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2020 Jun 16;1-13.